ARS Pharmaceuticals, Inc. (SPRY)

ARS Pharmaceuticals' stock price has been influenced by several events in the past six months. The company reported better-than-expected Q4 2025 earnings, with revenue surpassing forecasts, leading to a stock price increase, but the company also reported a net loss for 2025 and did not provide 2026 revenue guidance. The FDA approved the removal of the age requirement for neffy 1 mg, expanding eligibility to all patients weighing 33 lbs or greater, including children under four years old, but the stock tumbled nearly 6%. EURneffy 1 mg received a positive opinion for approval in the EU. Northland Capital initiated coverage with an "Outperform" rating and a $25 price target, and Leerink Partners raised its price target to $26, reinforcing bullish sentiment. Some analysts have flagged neffy's slow commercial uptake, and the absence of 2026 guidance has kept investor sentiment cautious. Neffy's sales were ramping quickly, with Q3 2025 sales hitting $31.3 million, and international approvals and partnerships were highlighted as diversifying commercialization risk.

The demand for neffy is likely to exhibit some seasonality, particularly around the "back-to-school" season, with higher demand during late summer and early fall. The company's "neffyinSchools" program supports this seasonal demand. Increased exposure to allergens during warmer months and school-related activities could contribute to seasonal peaks in demand.

ARS Pharmaceuticals, Inc. (SPRY) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for severe allergic reactions. Their primary product is neffy®, a needle-free epinephrine nasal spray for Type I allergic reactions, including anaphylaxis, approved by the FDA in August 2024 for adult and pediatric use. The company is also developing ARS-2, an intranasal epinephrine program for chronic spontaneous urticaria acute flares, currently in Phase 2b clinical trials.

ARS Pharmaceuticals has a growing global presence through partnerships and regulatory approvals. Neffy is being commercialized in the United States and has partnered with ALK-Abelló for distribution in European markets, including the UK, and has launched in Germany. Neffy has also received approvals in China (licensed to Pediatrix Therapeutics) and Australia (licensed to Alfresa Pharma). Domestically, ARS Pharmaceuticals has secured placement on national formularies such as OptumRx and Cigna.

ARS Pharmaceuticals' brand reputation has been shaped by the commercialization and regulatory milestones of neffy. The FDA approval of neffy and subsequent approval to remove the age requirement enhanced its appeal. An initial FDA delay in 2023 impacted confidence, but subsequent approval saw the stock surge. Caution has been expressed regarding neffy's slow launch and the absence of 2026 revenue guidance. Strong physician engagement, patient uptake, expanding payer access, and positive real-world data contribute positively to its reputation. Global expansion with approvals in China and Australia, and a positive CHMP opinion for EURneffy in Europe, also bolster its international standing.

ARS Pharmaceuticals has significant institutional ownership, with 191 institutional owners and shareholders holding approximately 90.03% of the shares, while insider ownership is around 8.19%. Major institutional owners include RA Capital Management, L.P., OrbiMed Advisors LLC, Deerfield Management Company, L.P., Rubric Capital Management LP, BlackRock, Inc., Vanguard Group Inc, State Street Corp, and Millennium Management Llc. Key individual insider owners include Richard E. Lowenthal, Sarina Tanimoto, Peter A. Thompson, and James E. Flynn.